Michael Okunewitch
Stock Analyst at Maxim Group
(1.73)
# 3,151
Out of 4,884 analysts
26
Total ratings
25%
Success rate
-2.39%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $4.06 | +762.07% | 2 | May 29, 2025 | |
| CTOR Citius Oncology | Downgrades: Hold | n/a | $5.29 | - | 2 | May 23, 2025 | |
| ANEB Anebulo Pharmaceuticals | Maintains: Buy | $6 → $3 | $1.68 | +78.57% | 2 | May 15, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $3.98 | +201.77% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $4 → $7 | $1.16 | +503.45% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $1.43 | +879.02% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.01 | +197.03% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $0.96 | +317.97% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.61 | +1,860.78% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $1.31 | +358.02% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.90 | +1,233.33% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.29 | +1,760.47% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.83 | +536.04% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $2.94 | +68,777.55% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $19.34 | +29.27% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.55 | +287.10% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.77 | +802.53% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.21 | +4,424.89% | 1 | Nov 30, 2021 |
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $4.06
Upside: +762.07%
Citius Oncology
May 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $5.29
Upside: -
Anebulo Pharmaceuticals
May 15, 2025
Maintains: Buy
Price Target: $6 → $3
Current: $1.68
Upside: +78.57%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $3.98
Upside: +201.77%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $4 → $7
Current: $1.16
Upside: +503.45%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $1.43
Upside: +879.02%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.01
Upside: +197.03%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $0.96
Upside: +317.97%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.61
Upside: +1,860.78%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.31
Upside: +358.02%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.90
Upside: +1,233.33%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.29
Upside: +1,760.47%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.83
Upside: +536.04%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $2.94
Upside: +68,777.55%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $19.34
Upside: +29.27%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.55
Upside: +287.10%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $2.77
Upside: +802.53%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $2.21
Upside: +4,424.89%